Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / VCAN

VCAN

Basics

Aliases:
This biomarker is also known as:
  • versican proteoglycan,
  • WGN1,
  • chondroitin sulfate proteoglycan 2,
  • versican core protein,
  • Large fibroblast proteoglycan,
  • Glial hyaluronate-binding protein,
  • WGN,
  • Chondroitin sulfate proteoglycan core protein 2,
  • CSPG2,
  • PG-M,
  • ERVR,
  • versican,
  • GHAP,

View in BioMuta

Description…

VCAN, or CSPG2, a large chondroitin sulfate proteoglycan, is a major component of the extracellular matrix. This secreted protein is involved in cell adhesion, proliferation, migration and angiogenesis and plays a central role in tissue morphogenesis and maintenance. It is may play a role in intercellular signaling. Mutations in the CSPG2 gene are the cause of Wagner syndrome type 1. Multiple transcript variants encoding different isoforms have been found for this gene.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Under Review

Overview

VCAN (CSPG2) was shown to localize to vascular-like structures in ovarian cancer but not in normal ovaries.

Performance Comment

VCAN, or CSPG2, was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of VCAN was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html